These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 11270920)

  • 21. Guanfacine Use in Children With Down Syndrome and Comorbid Attention-Deficit Hyperactivity Disorder (ADHD) With Disruptive Behaviors.
    Capone GT; Brecher L; Bay M
    J Child Neurol; 2016 Jul; 31(8):957-64. PubMed ID: 26936058
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Atomoxetine versus placebo in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: a double-blind, randomized, multicenter trial in Germany.
    Dittmann RW; Schacht A; Helsberg K; Schneider-Fresenius C; Lehmann M; Lehmkuhl G; Wehmeier PM
    J Child Adolesc Psychopharmacol; 2011 Apr; 21(2):97-110. PubMed ID: 21488751
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Guanfacine for the treatment of attention deficit hyperactivity disorder in children and adolescents.
    Rizzo R; Martino D
    Expert Rev Neurother; 2015 Apr; 15(4):347-54. PubMed ID: 25800130
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluating Matching-Adjusted Indirect Comparisons in Practice: A Case Study of Patients with Attention-Deficit/Hyperactivity Disorder.
    Shafrin J; Shrestha A; Chandra A; Erder MH; Sikirica V
    Health Econ; 2017 Nov; 26(11):1459-1466. PubMed ID: 27620206
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Guanfacine use in children with attention deficit hyperactivity disorder.
    Cohn LM; Caliendo GC
    Ann Pharmacother; 1997; 31(7-8):918-9. PubMed ID: 9220058
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A controlled trial of extended-release guanfacine and psychostimulants for attention-deficit/hyperactivity disorder.
    Wilens TE; Bukstein O; Brams M; Cutler AJ; Childress A; Rugino T; Lyne A; Grannis K; Youcha S
    J Am Acad Child Adolesc Psychiatry; 2012 Jan; 51(1):74-85.e2. PubMed ID: 22176941
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Growth hormone response to guanfacine in boys with attention deficit hyperactivity disorder: a preliminary study.
    Halperin JM; Newcorn JH; McKay KE; Siever LJ; Sharma V
    J Child Adolesc Psychopharmacol; 2003; 13(3):283-94. PubMed ID: 14642016
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Advances in the treatment of attention-deficit/hyperactivity disorder: a guide for pediatric neurologists.
    Wigal SB; Chae S; Patel A; Steinberg-Epstein R
    Semin Pediatr Neurol; 2010 Dec; 17(4):230-6. PubMed ID: 21183129
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Atomoxetine treatment of attention-deficit/hyperactivity disorder in young adults with assessment of functional outcomes: a randomized, double-blind, placebo-controlled clinical trial.
    Durell TM; Adler LA; Williams DW; Deldar A; McGough JJ; Glaser PE; Rubin RL; Pigott TA; Sarkis EH; Fox BK
    J Clin Psychopharmacol; 2013 Feb; 33(1):45-54. PubMed ID: 23277268
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of a mixed amphetamine salts compound in adults with attention-deficit/hyperactivity disorder.
    Spencer T; Biederman J; Wilens T; Faraone S; Prince J; Gerard K; Doyle R; Parekh A; Kagan J; Bearman SK
    Arch Gen Psychiatry; 2001 Aug; 58(8):775-82. PubMed ID: 11483144
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Guanfacine extended release as adjunctive therapy to psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder.
    Childress AC
    Adv Ther; 2012 May; 29(5):385-400. PubMed ID: 22610723
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cognitive Effects of Stimulant, Guanfacine, and Combined Treatment in Child and Adolescent Attention-Deficit/Hyperactivity Disorder.
    Bilder RM; Loo SK; McGough JJ; Whelan F; Hellemann G; Sugar C; Del'Homme M; Sturm A; Cowen J; Hanada G; McCracken JT
    J Am Acad Child Adolesc Psychiatry; 2016 Aug; 55(8):667-73. PubMed ID: 27453080
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect size of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder.
    Wigal T; Brams M; Gasior M; Gao J; Giblin J
    Postgrad Med; 2011 Mar; 123(2):169-76. PubMed ID: 21474905
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Possible influence of variant of the P-glycoprotein gene (MDR1/ABCB1) on clinical response to guanfacine in children with pervasive developmental disorders and hyperactivity.
    McCracken JT; Aman MG; McDougle CJ; Tierney E; Shiraga S; Whelan F; Arnold LE; Posey D; Ritz L; Vitiello B; Scahill L
    J Child Adolesc Psychopharmacol; 2010 Feb; 20(1):1-5. PubMed ID: 20166790
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Guanfacine treatment of hyperactivity and inattention in pervasive developmental disorders: a retrospective analysis of 80 cases.
    Posey DJ; Puntney JI; Sasher TM; Kem DL; McDougle CJ
    J Child Adolesc Psychopharmacol; 2004; 14(2):233-41. PubMed ID: 15319020
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder.
    Biederman J; Melmed RD; Patel A; McBurnett K; Konow J; Lyne A; Scherer N;
    Pediatrics; 2008 Jan; 121(1):e73-84. PubMed ID: 18166547
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Guanfacine for attention deficit and hyperactivity disorder in pediatrics: a systematic review and meta-analysis.
    Ruggiero S; Clavenna A; Reale L; Capuano A; Rossi F; Bonati M
    Eur Neuropsychopharmacol; 2014 Oct; 24(10):1578-90. PubMed ID: 25156577
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomised, double-blind, placebo-controlled trial of dexamphetamine in adults with attention deficit hyperactivity disorder.
    Paterson R; Douglas C; Hallmayer J; Hagan M; Krupenia Z
    Aust N Z J Psychiatry; 1999 Aug; 33(4):494-502. PubMed ID: 10483843
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of attention-deficit/hyperactivity disorder.
    Jadad AR; Boyle M; Cunningham C; Kim M; Schachar R
    Evid Rep Technol Assess (Summ); 1999 Nov; (11):i-viii, 1-341. PubMed ID: 10790990
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of the effects on blood pressure of abrupt cessation versus taper down of guanfacine extended-release tablets in adults aged 19 to 24 years.
    Kisicki JC; Fiske K; Lyne A
    Clin Ther; 2007 Sep; 29(9):1967-79. PubMed ID: 18035196
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.